Cargando…

Primary malignant melanoma of the trachea: A case report

Primary cancer of the trachea is rare and accounts for only 0.1–0.4% of all newly diagnosed respiratory tract cancers, worldwide. In the present study, a case of primary tracheal malignant melanoma, a particularly rare type of cancer, is reported. A 68-year-old male presented with a cough and bloody...

Descripción completa

Detalles Bibliográficos
Autores principales:	IMAI, HISAO, KIYOHARA, YOSHIO, YOSHIKAWA, SHUSUKE, KUSUTANI, NAO, ONO, AKIRA, TAIRA, TETSUHIKO, KENMOTSU, HIROTSUGU, HARADA, HIDEYUKI, NAITO, TATEAKI, MURAKAMI, HARUYASU, SANO, TAKEHISA, FUJI, HIROSHI, ENDO, MASAHIRO, NAKAJIMA, TAKASHI, TAKAHASHI, TOSHIAKI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301528/ https://www.ncbi.nlm.nih.gov/pubmed/25624894 http://dx.doi.org/10.3892/ol.2014.2782

Ejemplares similares

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
por: Kasahara, Norimitsu, et al.
Publicado: (2015)

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
por: Watanabe, Masaru, et al.
Publicado: (2018)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2015)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

The effects of advanced age and serum α(1)‐acid glycoprotein on docetaxel unbound exposure and dose‐limiting toxicity in cancer patients
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2017)

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
por: Ko, Ryo, et al.
Publicado: (2016)

Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis
por: Takinami, Masaki, et al.
Publicado: (2021)

Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy
por: Kobayashi, Haruki, et al.
Publicado: (2018)

Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities
por: Kobayashi, Haruki, et al.
Publicado: (2021)

Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer
por: Harada, Hideyuki, et al.
Publicado: (2016)

Acquired immunodeficiency associated with thymoma: a case report
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study
por: Mitsuya, Koichi, et al.
Publicado: (2019)

Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study
por: Naito, Tateaki, et al.
Publicado: (2017)

Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non–small-cell lung cancer
por: Naito, Tateaki, et al.
Publicado: (2017)

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy
por: Mamesaya, Nobuaki, et al.
Publicado: (2018)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
por: Mamesaya, Nobuaki, et al.
Publicado: (2023)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Miyawaki, Taichi, et al.
Publicado: (2021)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study
por: Aso, Sakiko, et al.
Publicado: (2022)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022)

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020)

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021)

Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2014)

High-dose proton beam therapy for sinonasal mucosal malignant melanoma
por: Fuji, Hiroshi, et al.
Publicado: (2014)

Days Spent at Home near the End of Life in Japanese Elderly Patients with Lung Cancer: Post hoc Analysis of A Prospective Study
por: Notsu, Mikako, et al.
Publicado: (2021)

Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System
por: Hosokawa, Masahito, et al.
Publicado: (2013)

Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy
por: Doshita, Kosei, et al.
Publicado: (2022)

Tracheal granuloma 7 years after extubation
por: Nakashima, Kazuhisa, et al.
Publicado: (2017)

Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer
por: Yonenaga, Yusuke, et al.
Publicado: (2021)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
por: Mamesaya, Nobuaki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nqcd24gqu8l0t1m96vgq5c5f5r